Kynam Capital reports 5.29% stake in CytomX
CytomX Therapeutics: Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang report beneficial ownership of 8,966,077 shares of common stock, equal to 5.29% as of 12/31/2025.
Rhea-AI Filing Summary
CytomX Therapeutics: Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang report beneficial ownership of 8,966,077 shares of common stock, equal to 5.29% as of 12/31/2025.
The filing states the holders have shared voting and shared dispositive power over those 8,966,077 shares and lists Delaware and United States citizenships for the reporting entities and person.
Positive
- None.
Negative
- None.
Insights
Large passive stake reported: 5.29% ownership reported as of 12/31/2025.
The filing shows 8,966,077 shares are beneficially owned collectively by Kynam Capital Management, LP, Kynam Capital Management GP, LLC and Yue Tang, with shared voting and dispositive power. The filing is a Schedule 13G-style passive ownership disclosure.
Because the report lists shared power rather than sole control, the stake appears nondispositive by a single holder; material impact on control is not evident from the excerpt. Subsequent filings or proxy disclosures would clarify any change in intent or voting behavior.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Kynam Capital report in CytomX (CTMX)?
Who are the filers on the Schedule 13G for CTMX?
What date is the ownership percentage based on in the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.